Emerging Infectious Diseases: a Review

  • Kevin WatkinsEmail author
Infectious Disease (J Glauser, Section Editor)
Part of the following topical collections:
  1. Infectious Disease


Purpose of Review

This review highlights some of the recent concerning emerging infectious diseases, a number of them specifically that the World Health Organization has categorized as priorities for research.

Recent Findings

Emerging and reemerging infectious diseases account for significant losses in not only human life, but also financially. There are a number of contributing factors, most commonly surrounding human behavior, that lead to disease emergence. Zoonoses are the most common type of infection, specifically from viral pathogens. The most recent emerging diseases in the USA are Emergomyces canadensis, the Heartland virus, and the Bourbon virus.


In addition to the aforementioned pathogens, the Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, Nipah virus, New Delhi metallo-ß-lactamase-1 Enterobacteriaceae, Rift Valley Fever virus, and Crimean-Congo Hemorrhagic Fever virus are reviewed. These pathogens are very concerning with a high risk for potential epidemic, ultimately causing both significant mortality and financial costs. Research should be focused on monitoring, prevention, and treatment of these diseases.


Emerging infectious diseases Reemerging infections Viral pathogens 


Compliance with Ethical Standards

Conflict of Interest

The author declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance

  1. 1.
    Hughes JM. Emerging infectious diseases: a CDC perspective. Emerg Infect Dis. 2001;7(3 Suppl):494–6. CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Morens DM, Fauci AS. Emerging infectious diseases in 2012: 20 years after the Institute of Medicine Report. MBio. 2012;3(6):e00494–12. Scholar
  3. 3.
    Kilpatrick AM, Randolph SE. Drivers, dynamics, and control of emerging vector-borne zoonotic diseases. Lancet. 2012;380(9857):1946–55. Scholar
  4. 4.
    Bloom DE, Black S, Rappuoli R. Emerging infectious disease: a proactive approach. Proc Natl Acad Sci U S A. 2017;114(16):4055–9. Scholar
  5. 5.
    Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1953–66. Scholar
  6. 6.
    Demmler GJ, Ligon BL. Severe acute respiratory syndrome (SARS): a review of the history, epidemiology, prevention, and concerns for the future. Semin Pediatr Infect Dis. 2003;14(3):240–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Hui DS, Chan PK. Severe acute respiratory syndrome and coronavirus. Infect Dis Clin N Am. 2010;24(3):619–38. Scholar
  8. 8.
    Peiris JS. Severe acute respiratory syndrome (SARS). J Clin Virol. 2003;28(3):245–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Shortridge KF. Severe acute respiratory syndrome and influenza: virus incursions from southern China. Am J Respir Crit Care Med. 2003;168(12):1416–20. Scholar
  10. 10.
    World Health Organization (2004) WHO guidelines for the global surveillance of severe acute respiratory syndrome (SARS).
  11. 11.
    Kumar V, Jung YS, Liang PH. Anti-SARS coronavirus agents: a patent review (2008-present). Expert Opin Ther Pat. 2013;23(10):1337–48. Scholar
  12. 12.
    Shehata MM, Gomaa MR, Ali MA, Kayali G. Middle East respiratory syndrome coronavirus: a comprehensive review. Front Med. 2016;10(2):120–36. Scholar
  13. 13.
    Sampathkumar P. Middle East respiratory syndrome: what clinicians need to know. Mayo Clin Proc. 2014;89(8):1153–8. Scholar
  14. 14.
    Rasmussen SA, Gerber SI, Swerdlow DL. Middle East respiratory syndrome coronavirus: update for clinicians. Clin Infect Dis. 2015;60(11):1686–9. Scholar
  15. 15.
    •• World Health Organization (2017) WHO MERS-CoV Global Summary and Assessment of Risk. This article gives the majority of a summary of perhaps most significant recent emerging infectious disease in terms of both mortality and number of cases. It describes not only the cases noted in the Middle East, but additionally the South Korean outbreak as well as cases imported to nations globally.
  16. 16.
    Al-Tawfiq JA, Kattan RF, Memish ZA. Middle East respiratory syndrome coronavirus disease is rare in children: an update from Saudi Arabia. World J Clin Pediatr. 2016;5(4):391–6.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Kim SW, Park JW, Jung HD, Yang JS, Park YS, Lee C, et al. Risk factors for transmission of Middle East respiratory syndrome coronavirus infection during the 2015 outbreak in South Korea. Clin Infect Dis. 2017;64(5):551–7. PubMedCrossRefGoogle Scholar
  18. 18.
    Arabi YM, Arifi AA, Balkhy HH, Najm H, Aldawood AS, Ghabashi A, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med. 2014;160(6):189–97. Scholar
  19. 19.
    Madani TA et al (2015) Infection Prevention and Control Guidelines for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection, 3rd Ed.
  20. 20.
    Chan JF, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Inf Secur. 2013;67(6):606–16. Scholar
  21. 21.
    Mo Y, Fisher D. A review of treatment modalities for Middle East respiratory syndrome. J Antimicrob Chemother. 2016;71(12):3340–50.CrossRefPubMedGoogle Scholar
  22. 22.
    Al Ghamdi M, et al. Treatment outcomes for patients with middle eastern respiratory syndrome coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia. BMC Infect Dis. 2016;16:174. Scholar
  23. 23.
    McMullan LK, et al. A new Phlebovirus associated with severe febrile illness in Missouri. N Engl J Med. 2012;367(9):834–41. Scholar
  24. 24.
    Pastula DM, et al. Notes from the field: heartland virus disease—United States, 2012-2013. MMWR Morb Mortal Wkly Rep. 2014;63(12):270–1.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Muehlenbachs A, Fata CR, Lambert AJ, Paddock CD, Velez JO, Blau DM, et al. Heartland virus associated death in Tennessee. Clin Infect Dis. 2014;59(6):845–50. Scholar
  26. 26.
    • Wormser GP, Pritt B. Update and commentary on four emerging tick-borne infections. Infect Dis Clin N Am. 2015;29(2):371–81. Discusses a recent emerging pathogen in the USA with the most cases. CrossRefGoogle Scholar
  27. 27.
    Kosoy OI, Lambert AJ, Hawkinson DJ, Pastula DM, Goldsmith CS, Hunt DC, et al. Novel Thogotovirus associated with febrile illness and death, United States, 2014. Emerg Infect Dis. 2015;21(5):760–4. Scholar
  28. 28.
    Savage HM, Burkhalter KL, Godsey MS Jr, Panella NA, Ashley DC, Nicholson WL, et al. Bourbon virus in field-collected ticks, Missouri, USA. Emerg Infect Dis. 2017;23(12):2017–22. Scholar
  29. 29.
    Sherrini BA, Chong TT. Nipah encephalitis—an update. Med J Malaysia. 2014;69(Supplement A):103–11.PubMedGoogle Scholar
  30. 30.
    Luby SP. The pandemic potential of Nipah virus. Antivir Res. 2013;100(1):38–43. Scholar
  31. 31.
    Geisbert TW, Mire CE, Geisbert JB, Chan YP, Agans KN, Feldmann F, et al. Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody. Sci Transl Med. 2014;6(242):242ra82. Scholar
  32. 32.
    Schwartz IS, Sanche S, Wiederhold NP, Patterson TF, Sigler L. Emergomyces canadensis, a dimorphic fungus causing fatal systemic human disease in North America. Emerg Infect Dis. 2018;24(4):758–61. Scholar
  33. 33.
    Schwartz IS, Maphanga TG, Govender NP. Emergomyces: a new genus of dimorphic fungal pathogens causing disseminated disease among immunocompromised persons globally. Curr Fungal Infect Rep. 2018;12(1):44–50. Scholar
  34. 34.
    Johnson AP, Woodford N. Global spread of antibiotic resistance: the example of New Delhi metallo-ß-lactamase (NDM)-mediated carbapenem resistance. J Med Microbiol. 2013;62(Pt. 4):499–513. Scholar
  35. 35.
    Walsh TR, Toleman MA. The new medical challenge: why NDM-1? Why Indian? Expert Rev Anti-Infect Ther. 2011;9(2):137–41. Scholar
  36. 36.
    Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10(9):597–602. Scholar
  37. 37.
    Walsh TR, Toleman MA. The emergence of pan-resistant Gram-negative pathogens merits a rapid global political response. J Antimicrob Chemother. 2012;67(1):1–3. Scholar
  38. 38.
    Mansfield KL, Banyard AC, McElhinney L, Johnson N, Horton DL, Hernández-Triana LM, et al. Rift Valley fever virus: a review of diagnosis and vaccination, and implications for emergence in Europe. Vaccine. 2015;33(42):5520–31. Scholar
  39. 39.
    Nicholas DE, Jacobsen KH, Waters NM. Risk factors associated with human Rift Valley fever virus infection: systematic review and meta-analysis. Tropical Med Int Health. 2014;19(12):1420–9. Scholar
  40. 40.
    Shayan S, Bokaean M, Shahrivar MR, Chinikar S. Crimean-Congo hemorrhagic fever. Lab Med. 2015;46(3):180–9. Scholar
  41. 41.
    Bente DA, Forrester NL, Watts DM, McAuley AJ, Whitehouse CA, Bray M. Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antivir Res. 2013;100(1):159–89. Scholar
  42. 42.
    • Mendoza EJ et al. (2018) Crimean-Congo haemorrhagic fever virus: past, present and future insights for animal modelling and medical countermeasures. Zoonoses Public Health 1–16. This article highlights potential management strategies of the most widespread tick-borne viral disease globally.
  43. 43.
    Papa A, Mirazimi A, Köksal I, Estrada-Pena A, Feldmann H. Recent advances in research on Crimean-Congo hemorrhagic fever. J Clin Virol. 2015;64:137–43. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Cleveland Clinic Foundation, Akron General Medical CenterAkronUSA

Personalised recommendations